QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability ...
The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback